Document Detail


Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
MedLine Citation:
PMID:  19525519     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We initiated a randomized controlled clinical trial to assess the effect of sirolimus on disease progression in patients affected by autosomal dominant polycystic kidney disease (ADPKD). Here we report the preliminary safety results of the first 6 months of treatment. METHOD: A total of 25 patients were randomized to sirolimus 2 mg/day and 25 patients to no treatment except standard care. Treatment adherence was monitored electronically. At baseline and at Month 6, laboratory parameters were analysed and the urinary protein profile in 24-h urine collections was determined. RESULTS: Both treatment groups were well balanced for age, sex and renal function. In 94.1 +/- 11.4% of the study days, patients in the sirolimus group were exposed to the drug when assuming a therapeutic efficacy duration of 30 h. At Month 6, the mean sirolimus dose and trough level were 1.28 +/- 0.71 mg/day and 3.8 +/- 1.9 microg/l, respectively. Glomerular (albumin, transferrin, IgG) and tubular (retinol-binding protein, alpha(1)-microglobulin) protein excretion remained unchanged. Glomerular filtration rate also did not change significantly. Haematological parameters were similar in both groups, except for a mild reduction of the mean corpuscular volume of erythrocytes in patients receiving sirolimus. Lipid levels were similar in both groups. Adverse events were transient and mild, and no grade 3 or 4 events occurred. The incidence of infections was similar in the sirolimus group (80%) and the standard group (88%). The most common gastrointestinal adverse events were mucositis (72% in the sirolimus group versus 16% in the standard group, P = 0.0001) and diarrhoea (36% in the sirolimus versus 20% in the standard group, P = 0.345). CONCLUSION: Treatment of ADPKD patients with sirolimus with a dose of 1-2 mg/day is safe and does not cause proteinuria or impairment of GFR. Treatment adherence was excellent. (ClinicalTrials.gov number, NCT00346918.).
Authors:
Andreas L Serra; Andreas D Kistler; Diane Poster; Fabienne Krauer; Oliver Senn; Shagun Raina; Ivana Pavik; Katharina Rentsch; Axel Regeniter; Dominik Weishaupt; Rudolf P W??thrich
Related Documents :
24694779 - Successful foot salvage with microvascular flaps in diabetic patients.
23531549 - Short-term effects of proximal femoral derotation osteotomy on kinematics in ambulatory...
20230379 - Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up.
23804869 - Hematologic alterations in patients with functionally univentricular hearts.
23395249 - Arthroscopic versus open cam resection in the treatment of femoroacetabular impingement.
23275039 - Intravitreal dexamethasone implant (ozurdex) for macular edema secondary to retinitis p...
1567629 - Surgical treatment of cardiovascular complications in marfan syndrome: a 27-year experi...
2408659 - Retinal pigment epithelial detachments in the elderly: classification and outcome.
10385159 - Repeat balloon dilation of congenital valvar aortic stenosis: immediate results and mid...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-06-13
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  24     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-16     Completed Date:  2010-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  3334-42     Citation Subset:  IM    
Affiliation:
Division of Nephrology, University Hospital Z??rich, Institute of Physiology, Switzerland.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00346918
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Erythrocyte Indices / drug effects
Female
Humans
Immunosuppressive Agents / adverse effects*
Kidney / drug effects,  physiology
Lipids / blood
Male
Medication Adherence
Polycystic Kidney, Autosomal Dominant / drug therapy*
Sirolimus / adverse effects*,  blood
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Lipids; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cryptococcal granulomatous interstitial nephritis and dissemination in a patient with untreated lupu...
Next Document:  Risk factors for infection with highly pathogenic influenza A virus (H5N1) in commercial chickens in...